Dynamic quotes: Off
|
ETFs with NVO as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 4.67% | Merrill Lynch Pharmaceutical HOLDRS (PPH) | +1.84 (4.36%) |
| 4.3% | WCM BNY Mellon Focused Growth ADR ETF (AADR) | +4.35 (15.11%) |
| 3.2% | Columbia Select Large Cap Growth ETF (RWG) | -1.67 (-5.30%) |
| 2.57% | Direxion Developed Markets Bull 3x Shares (DZK) | +17.42 (50.29%) |
| 2.28% | BLDRS Europe 100 ADR Index Fund (ADRU) | +1.86 (9.02%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Novo Nordisk was formed in 1989 by a merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. Novo Industri A/S was the continuing company and its name was changed to Novo Nordisk A/S. The business activities of Nordisk Gentofte were established in 1923 by August Krogh, H. C. Hagedorn and A. Kongsted, and the business activities of Novo Industri were established in 1925 by Harald and Thorvald Pedersen. The business of both companies from the beginning was production and sale of insulin for the treatment of diabetes. In November 2000 Novo Nordisk spun off its industrial enzyme division into a separate business, Novozymes A/S. Following the spin off, Novo Nordisk became a focused healthcare company, with close to 90 years of experience in diabetes care. Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ |
| Quarterly EPS Est: | |
| PEG Ratio: | 1.39 |
|
Mean Recommendation: View Summary / View All |
2.5 |
Data is provided by Zacks Investment Research